STAT3 and amyloidosis: While the beneficial effects of drugs that non-specifically inhibit STAT3 have been reported in transgenic mouse models of amyloidosis [48, 49], direct evidence that STAT3-specific pharmacologic inhibitor attenuates amyloid deposition and ameliorates amyloid-induced neurovascular dysfunction is lacking.